Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Diffuse Intrinsic Pontine Glioma × TIC10 compound × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Glioblastoma 2 Endometrial Neoplasms 2 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Meningioma 1 Glioma 1 Endometrial Cancer Recurrent 1 Diffuse Intrinsic Pontine Glioma 1 Breast Neoplasms, Male 1

Interventions

Temozolomide 7 Radiotherapy 3 nimotuzumab 2 Everolimus 2 Erlotinib Hydrochloride 2 Cyclophosphamide 2 Bevacizumab 2 tovorafenib 1 ribociclib 1 palbociclib 1 olutasidenib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vinorelbine 1 Valproic Acid 1 Topotecan 1 TIC10 compound 1 Radiation 1 Proto-Oncogene Proteins c-akt 1 Phosphatidylinositol 3-Kinases 1 Lomustine 1 Irinotecan 1 GDC-0084 1 Etoposide 1 Drug Therapy 1 Doxorubicin 1 Diphtheria-Tetanus Vaccine 1 Dasatinib 1 Cilengitide 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡